Press Releases
Debiopharm S.A. inaugurates a new State-of-the-Art Galenic Unit in Gland, Switzerland
H3 Pharma announces promising developments for the treatment of Alzheimer´s disease
Debiopharm S.A. reports study revealing that EPI-HNE4 offers protection against acute lung injury
Debiopharm SA a acquis un nouveau bâtiment à Lausanne et projette de déménager vers la fin 2004
H3 Pharma Licenses in Phase II Product for Stomach Cancer and Acquires Stake in a Human mAb Discovery Company Specializing…
Swiss drug developer Debiopharm announces FDA approval of Trelstar TM LA for therapeutic use
Debiopharm and Aurigene sign agreement for the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology…
Dyax Corp. and Debiopharm S.A. report initiation of phase II clinical trial with EPI-HNE-4 for cystic fibrosis
Swiss drug developer Debiopharm S.A. achieves another success in the development of molecules for theraeutic use